Organization | An-Najah National University

An-Najah National University Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2019

NCT03288571

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

An-Najah National University | An Najah National University Hospital | Zaher Nazzal

Active Ingredients

Drugs in Phase 3 Trials (2)

oxycodone (oxycontin) (1 trial)

pregabalin (lyrica) (1 trial)

Drugs in Phase 2 Trials (1)

wharton's jelly mesenchymal stem cells (1 trial)

Drugs in Other Trials (7)

candesartan (atacand) (1 trial)

dapagliflozin (farxiga) (1 trial)

dexmedetomidine (precedex) (1 trial)

enalapril (vasotec) (1 trial)

losartan (cozaar) (1 trial)

ramipril (altace) (1 trial)

valsartan (diovan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetic Nephropathies (Phase 2)

Kidney Diseases (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 10